Logo www.CancerITIM.org


  5th International






April 24-27, 2017


Prague, Czech Republic



Topics to be discussed:



Inflammation and immunity in the tumor microenvironment


Regulatory and effector mechanisms in the tumor immunoenvironment  


Tumor microenvironment and cancer immunotherapy


Preclinical models of cancer immunotherapy


Cancer immunotherapy : Clinical trials 


Cancer immunotherapy: Regulatory cells and cytokines


Cancer immunotherapy: New approaches


Cancer biomarkers and immunomonitoring in cancer clinical trials




Prague, Czech Rep             April 24-27, 2017



April 24, 2017



Registration                                                    13:30 – 18:30                         



Conference opening ceremony       14:00 – 14:30


Conference opening 

Michael R. Shurin (Chair, CITIM Organizing Committee)

Greetings (Cancer Microenvironment Society (ICMS), Association for Cancer Immunotherapy (CIMT), PIVAC, Israeli Society for Cancer Research, ENCI (European Network Cancer Immunotherapy), Czech Immunological Society (CIS))

Welcome remarks and Information

            Luca Vannucci (Chair, Local Organizing Committee)

Blanka Říhová (President of the Czech Immunological Society)

Viktor Umansky (CITIM Organizing Committee)



KEYNOTE LECTURE                                                            14:30 – 15:30


Chair: Viktor Umansky (Heidelberg, Germany)

Giorgio Trinchieri

NIH Distinguished Investigator

Director, Cancer and Inflammation Program

Center for Cancer Research, NCI, NIH

Associate Director for Basic Science

Trans-NIH Center for human Immunology

Bethesda, Maryland, USA


Cancer as a disease of the symbiont/metaorganism





PLENARY SESSION 1                                                           15:40 – 17:40

Immunity and the malignant process I

Chair: Dmitry Gabrilovich (Philadelphia, PA, USA)

Chair: Blanka Říhová (Prague, Czech Rep)



Isaac Witz (Tel Aviv, Israel)                                                    15:40 - 16:10

The metastatic microenvironment: Tumor-associated and microenvironmental drivers of metastasis


Sven Brandau (Essen, Germany)                                          16:10 - 16:40

Novel functions of toll-like receptors in tumor immunity


Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)           16:40 - 17:10  

High fat diet and leptin drive myeloid-derived suppressor cells (MDSC) that protect against metabolic dysfunction, but promote tumor progression


Paul Lehmann (Cleveland, OH, USA)                                   17:10 - 17:40

The natural history of autoreactive (tumor reactive?) T cells



Coffee break                                                               17:40 – 18:00



PLENARY SESSION 2                                                           18:00 – 19:35

Immunity and the malignant process II

Chair: Michal Baniyash (Jerusalem, Israel)

Chair: Kelvin Lee (Buffalo, NY, USA)


Elena Voronov (Beer Sheva, Israel)                                      18:00 – 18:25

A dual effect of IL-1 alpha in colon inflammation and inflammation-related colon cancer


Dmitriy W. Gutkin (Pittsburgh, PA, USA)                              18:25 – 18:45

Immune infiltrate in premalignant lesions


Natalia Aptsiauri (Granada, Spain)                                       18:45 – 19:05

Correlation between HLA class I and PD-L1/PD1 expression in human tumors


Nathan Karin (Haifa, Israel)                                                   19:05 – 19:35

The role of chemokines in regulating tumor immunity 





Welcome reception, Hotel Ambassador         19:45 – 22:00




April 25, 2017


Keynote Presentation                                                           8:20 – 9:05


Chair: Arthur Hurwitz (Lexington, MA, USA)


Rolf Kiessling (Stockholm, Sweden)

Counteracting tumor induced immune suppression



PLENARY SESSION 3                                                           9:05 – 10:55

Regulatory pathways in the tumor immunoenvironment I


Chair: Viktor Umansky (Heidelberg, Germany)

Chair: Joost J. Oppenheim (Frederick, MD, USA)


Federico Garrido (Granada, Spain)                                      9:05 - 9:35

Rejection versus escape: The tumour MHC dilemma


Dmitry I. Gabrilovich (Philadelphia, PA, USA)                      9:35 - 10:05

Regulation of myeloid cell differentiation in cancer




The Peripheral Nervous System in the tumor microenvironment


Anton A. Keskinov (Pittsburgh, PA, USA)                            10:05 - 10:20

Sensory neurons and the tumor immunoenvironment


Yuri Bunimovich (Pittsburgh, PA, USA)                                10:20 - 10:35

Neuroglial support of the melanoma microenvironment


Michael R. Shurin (Pittsburgh, PA, USA)                              10:35 - 10:55

Cancer-PNS-Immune axis: New concept and new data



Coffee break                                                   10:55 – 11:15 



PLENARY SESSION 4                                                           11:15 – 13:25

Regulatory pathways in the tumor immunoenvironment II


     Chair: Isaac Witz (Tel Aviv, Israel)

     Chair: Lenka Zdrazilova-Dubska (Brno, Czech Rep)


Zvi G. Fridlender (Jerusalem, Israel)                         11:15 - 11:40

Tumor related neutrophils - important modulators of the immune reaction to cancer


Viktor Umansky (Heidelberg, Germany)                               11:40 - 12:05

Immunoregulatory circuits in the melanoma microenvironment


Adit Ben-Baruch (Tel Aviv, Israel)                                       12:05 - 12:35

Inflammation-driven tumor-stroma interactions in breast cancer


Jonathan Weiss (Frederick, MD, USA)                                 12:35 - 12:55

Crosstalk between macrophage metabolism and tumor progression


Blanka Říhová (Prague, Czech Rep)                        12:55 - 13:25

Polymeric prodrugs act as endogeneous vaccines


Lunch break                                                    13:25 – 14:20



PLENARY SESSION 5                                                           14:20 – 16:40

Regulatory pathways in the tumor immunoenvironment III


       Chair: Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)

       Chair: Graham Pawelec (Tübingen, Germany)


Michal Baniyash (Jerusalem, Israel)                         14:20 - 14:50

The plasticity of myeloid-derived suppressor cells: Clinical implications


Kelvin Lee (Buffalo, NY, USA)                                               14:50 - 15:20

Food and shelter and cancer progression


Salem Chouaib (Villejuif, France)                                        15:20 - 15:50

Regulation of immune resistance and immune suppression by hypoxia


Lenka Zdrazilova-Dubska (Brno, Czech Rep)                      15:50 - 16:10

Immunomonitoring of patients treated by cancer immunotherapy: rationale and showcases


Udo Gaipl (Erlangen, Germany)                                            16:10 - 16:40

Immune modulatory properties of radiotherapy - rationales for combination with immunotherapy



Coffee break                                                   16:40 – 17:20 



POSTER SESSION                                                                16:40 – 17:55





Prague overview sightseeing walking tour for CITIM-2017 participants      18:00 – 20:00




April 26, 2017


Keynote Presentation                                                           8:30 – 9:15


Chair: Natalia Aptsiauri (Granada, Spain)


Graham Pawelec (Tübingen, Germany)

Immune signatures predicting responses to immunomodulatory antibody therapy



PLENARY SESSION 6                                                           9:20 – 11:20

Inflammation, microbiota and cancer: regulatory mechanisms


                                                                                    Chair: Jay A. Berzofsky (Bethesda, MD, USA)

Chair: Catherine Sautes-Fridman (Paris, France)


Ron Apte (Beer-Sheva, Israel)                                               9:20 – 9:45

The microenvironment shifts the balance between inflammation and immunity in tumors


Janko Kos (Ljubljana, Slovenia)                                            9:45 – 10:05

Cystatin F dependent regulation of NK and T cell cytotoxicity


Miloslav Kverka (Prague, Czech Rep)                                  10:05 – 10:25

Diet and microbiota as modulators of gut inflammation and colon cancer


Anahid Jewett (Los Angeles, CA, USA)                                10:25 – 10:50

Systemic regulation of super-charged NK cell function by intestinal microflora in BLT humanized mice leads to lysis, growth inhibition and balanced differentiation of Cancer Stem Cells


Luca Vannucci (Prague, Czech Rep)                                    10:50 – 11:15

Stroma and immunity cross-talk build the tumor microenvironment


Mathias Chamaillard (Lille, France)                                      11:15 – 11:35

Remote control of intestinal tumorigenesis by the gut microbiota



Coffee break                                                   11:35 – 11:50



PLENARY SESSION 7                                                           11:50 – 14:10

Cancer immunotherapy I: New concepts and clinical data


Chair: Esteban Celis (Augusta, GA, USA)

Chair: Eitan Yefenof (Jerusalem, Israel)


Jay A. Berzofsky (Bethesda, MD, USA)                                11:50 – 12:20

Cancer Vaccine Strategies: Translation from mice to human clinical trials


Wolf H. Fridman (Paris, France)                                            12:20 – 12:50

Integration of molecular and immune classifications in human cancers: a guide for immunotherapies


Gurkamal S. Chatta (Buffalo, NY, USA)                                12:50 – 13:15

Chemokine modulation in Genito-urinary malignancies


Yulia Nefedova (Philadelphia, PA, USA)                               13:15 – 13:35

Regulation of tumor cell survival by myeloid cells in the bone marrow microenvironment


Thomas Sayers (Frederick, MD, USA)                                  13:35 – 14:00

Sensitization of melanoma cells to caspase-8-dependent cell death by specific 17beta-hydroxywithanolides



Lunch break                                                    14:00 – 14:50



PLENARY SESSION 8                                                           14:50 – 16:40

Cancer immunotherapy II: New targets and models


Chair: Wolf Fridman (Paris, France)

Chair: Per thor Straten (Herlev, Denmark)


Yasmin Thanavala (Buffalo, NY, USA)                                 14:50 – 15:10

Immunosuppressive pathways in HCC patients and beneficial immunomodulation following sorafenib therapy


Esteban Celis (Augusta, GA, USA)                                       15:10 – 15:35

Peptide vaccines for cancer can be effective, when used properly


Dmitri Loukinov (Rockville, MD, USA)                                  15:35 – 15:55

BORIS molecule is an attractive target for efficient immunotherapy of cancer


Arthur Hurwitz (Lexington, MA, USA)                                   15:55 – 16:20

Enhancing T cell responses to promote more durable tumor immunity


Benjamin Sredni (Ramat-Gan, Israel)                                   16:20 – 16:40

Redox modulation of adjacent thiols in VLA-4 by the immunomodulatory AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state



Coffee break                                                   16:40 – 17:00



PLENARY SESSION  9  Selected presentations                  17:00 – 17:50


                                                                        Chair: Adit Ben-Baruch (Tel Aviv, Israel)

Chair: Sjoerd H. van der Burg (Leiden, The Netherlands)


Tali Feferman (Rechovot, Israel)

Hypoxia restricts CTL-mediated tumor rejection: insights from live intratumoral imaging


Cecile Gouttefangeas (Tübingen, Germany)

A new -toll like receptor ligand as strong adjuvant for peptide vaccination






PLENARY SESSION 10                                                         18:00 – 19:50

Cancer immunotherapy III: Novel approaches and perspectives


Chair: Angel Porgador (Beer Sheva, Israel)

Chair: Udo Gaipl (Erlanger, Germany)


Jiřina Bartůňková (Prague, Czech Rep)                               18:00 – 18:20

Cell-based immunotherapy for solid tumors


Lea Eisenbach (Rehovot, Israel)                                           18:20 – 18:50

Anti-tumor vaccines: simple, sophisticated, combined

Catherine Sautes-Fridman (Paris, France)                          18:50 – 19:20

The functional diversity of intratumoral T cells in clear cell renal cell cancer


William J. Murphy (Sacramento, CA, USA)                          19:20 – 19:50

Impact of obesity on T cell exhaustion and effects on immunotherapy


April 27, 2017


Keynote Presentation                                                           8:30 – 9:15


Chair: Luca Vannucci (Prague, Czech Rep)


Robert Ferris (Pittsburgh, PA, USA)

Novel immunotherapeutic strategies and combinations to overcome immune escape in head and neck cancer



PLENARY SESSION 11                                                         9:20 – 11:30

Cancer immunotherapy IV: Novel applications and mechanisms


                                                                                    Chair: Federico Garrido (Granada, Spain)

Chair: Qing Yi (Cleveland, OH, USA)


Joost J. Oppenheim (Frederick, MD)                                    9:20 – 9:50

Curative immunotherapeutic strategy for the treatment of big CT26 and other tumors in mice


Per thor Straten (Herlev, Denmark)                                      9:50 – 10:20

Cancer therapy using T cells and running shoes


Sjoerd H. Van der Burg (Leiden, The Netherlands)              10:20 – 10:50

Combination of non-immunogenic cell death inducing chemotherapy and immunotherapy for improved tumor immunity


Shimon Slavin (Tel Aviv, Israel)                                            10:50 – 11:10

Innovative immunotherapy for prevention and treatment of relapse following conventional chemotherapy or stem cell transplantation


Sebastian Bunk (Tübingen, Germany)                                  11:10 – 11:30

Discovery and validation of TCRs for immunotherapeutic application



Coffee break                                                   11:30 – 11:50



PLENARY SESSION 12                                                         11:50 – 14:10

Cancer immunotherapy V: New approaches and rationales


Chair: Ron Apte (Beer Sheva, Israel)

Chair: Paul Lehmann (Cleveland, OH, USA)


Eitan Yefenof (Jerusalem, Israel)                                          11:50 – 12:20

MicroRNAs as diagnostic and therapeutic tools in leukemia


Yona Keisari (Tel Aviv, Israel)                                               12:20 – 12:50

Development of an Integrated Novel Radiotherapy and Immunotherapy cancer treatment: The journey from the pre-clinical to clinical trials


Marek Kovář (Prague, Czech Rep)                                        12:50 – 13:10

Complexes of IL-2 and anti-IL-2 mAb in cancer immunotherapy


Fabrizio Mattei (Rome, Italy)                                                 13:10 – 13:40

Microfluidic technology as a new tool to investigate cancer and immune cells crosstalk for immunotherapy


Lunch break                                        13:40 – 14:30



PLENARY SESSION  13   Best Abstract presentations         14:30 – 15:20


Chair: Mads Andersen (Herlev, Denmark)

Chair: Anahid Jewett (Los Angeles, CA, USA)









Coffee break                                                   15:20 – 15:40



PLENARY SESSION 14                                                         15:40 – 17:50

Cancer immunotherapy VI: New approaches and rationales


Chair: Rolf Kiessling (Stockholm, Sweden)

Chair: William Murphy (Sacramento, CA, USA)


Angel Porgador (Beer Sheva, Israel)                                    15:40 – 16:10

Natural Killer Immunity and Cancer Immunome


Georgi Guruli (Richmond, VA, USA)                                     16:10 – 16:30

Monitoring dendritic cells trafficking in mice using Multi-Spectral Imaging


Mansour Haeryfar (London, Ontario, Canada)                      16:30 – 16:50

MAIT Cells in Colorectal Carcinoma: Friend or Foe?


Qing Yi (Cleveland, OH, USA)                                               16:50 – 17:20

New T cell subsets for cancer adoptive cell therapy


Mads Andersen (Herlev, Denmark)                                       17:20 – 17:50

Anti-regulatory T cells: An alternative approach to target immunosuppressive mechanisms





Anatoli Malyguine


Natalia AptsiauriIntroduction to CITIM-2019




Banquet          19:30